A Phase II Study of Pelareorep (REOLYSIN(®)) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with 1 and 5-year survival rates of ~18% and 7% respectively. FOLFIRINOX or gemcitabine in combination with nab-paclitaxel are standard treatment options for metastatic disease. However, both regimens are more toxic than gemcitabine alone...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahalingam, Devalingam, Goel, Sanjay, Aparo, Santiago, Patel Arora, Sukeshi, Noronha, Nicole, Tran, Hue, Chakrabarty, Romit, Selvaggi, Giovanni, Gutierrez, Andres, Coffey, Matthew, Nawrocki, Steffan T., Nuovo, Gerard, Mita, Monica M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025223/
https://www.ncbi.nlm.nih.gov/pubmed/29799479
http://dx.doi.org/10.3390/cancers10060160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025223/
https://www.ncbi.nlm.nih.gov/pubmed/29799479
http://dx.doi.org/10.3390/cancers10060160

Ejemplares similares